| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Ulrich Germing | Q71780112 |
| Peter Valent | Q56697676 | ||
| P2093 | author name string | Igor Theurl | |
| Hans-Peter Horny | |||
| Karl Sotlar | |||
| Rainer Oberbauer | |||
| Ulrich Jäger | |||
| Olivier Hermine | |||
| Wolfgang R Sperr | |||
| Guntram Büsche | |||
| Klaus Geissler | |||
| Richard Moriggl | |||
| Marie C Béné | |||
| Reinhard Stauder | |||
| Peter Bettelheim | |||
| Michael Pfeilstöcker | |||
| Wolfgang Füreder | |||
| Jürg Schwaller | |||
| Iris Z Uras | |||
| P2860 | cites work | Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1 | Q24336627 |
| The human side of hypoxia-inducible factor | Q24646951 | ||
| Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo | Q24685620 | ||
| Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review | Q26750731 | ||
| Erythroid burst formation in cultures of bone marrow and peripheral blood from patients with refractory anemia | Q70439559 | ||
| The adhesion molecule E-cadherin and a surface antigen recognized by the antibody 9C4 are selectively expressed on erythroid cells of defined maturational stages | Q70893497 | ||
| Improved method for diagnosis of polycythemia vera based on flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture | Q71937860 | ||
| Interleukin-10 inhibits erythropoietin-independent growth of erythroid bursts in patients with polycythemia vera | Q77218342 | ||
| Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma | Q77453541 | ||
| What constitutes normal hemoglobin concentration in community-dwelling disabled older women? | Q80912464 | ||
| Anaemia of the elderly (AOE): does it exist and does it matter in clinical practice? | Q82218002 | ||
| The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70 | Q89777415 | ||
| Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome | Q46960830 | ||
| Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions | Q47124670 | ||
| Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia | Q48100617 | ||
| Bone marrow findings in blast phase of polycythemia vera | Q49504954 | ||
| Anemia at older age: etiologies, clinical implications and management | Q49988753 | ||
| Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes. | Q50506267 | ||
| Immunophenotypic analysis of erythroid dysplasia and its diagnostic application in myelodysplastic syndromes. | Q50523970 | ||
| A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. | Q50578930 | ||
| New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types. | Q53189055 | ||
| Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. | Q53281116 | ||
| Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing. | Q53412376 | ||
| More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia. | Q55120146 | ||
| Anemia in Pregnancy | Q56341634 | ||
| Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia | Q57217591 | ||
| Deficiency of pluripotent hemopoietic progenitor cells in myelodysplastic syndromes | Q57756710 | ||
| Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors | Q26777265 | ||
| How the Target Hemoglobin of Renal Anemia Should Be | Q26783623 | ||
| Primitive and definitive erythropoiesis in mammals | Q26851586 | ||
| From stem cell to red cell: regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin modifications | Q26860339 | ||
| The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia | Q27853375 | ||
| Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS) | Q28066544 | ||
| Transcriptional regulation of erythropoiesis: an affair involving multiple partners | Q28200921 | ||
| Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family | Q28203556 | ||
| Identification of erythroferrone as an erythroid regulator of iron metabolism | Q28240988 | ||
| MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4 | Q28251320 | ||
| Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor | Q28288945 | ||
| Acute erythremic myelosis (true erythroleukaemia): a variant of AML FAB-M6 | Q28360437 | ||
| Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes | Q28392451 | ||
| Rescue of erythroid development in gene targeted GATA-1- mouse embryonic stem cells | Q28510862 | ||
| Anemia in the elderly: a consequence of aging? | Q30238892 | ||
| Negative autoregulation by FAS mediates robust fetal erythropoiesis | Q33300418 | ||
| JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. | Q33371084 | ||
| Hemolytic anemia in adults: main causes and diagnostic procedures | Q33400568 | ||
| Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point | Q33615967 | ||
| Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease | Q33839857 | ||
| Molecular liaisons between erythropoiesis and iron metabolism | Q33948684 | ||
| Anemia and aging: an overview of clinical, diagnostic and biological issues | Q34238927 | ||
| Transcriptional control of erythropoiesis: emerging mechanisms and principles. | Q34700755 | ||
| An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia | Q35127943 | ||
| Emerging EPO and EPO receptor regulators and signal transducers | Q35692391 | ||
| Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis | Q35798280 | ||
| The molecular regulation of iron metabolism | Q35901908 | ||
| Polycythemia vera and other primary polycythemias | Q36051872 | ||
| The brain erythropoietin system and its potential for therapeutic exploitation in brain disease | Q36455213 | ||
| Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference | Q36719937 | ||
| Erythroblastic islands: niches for erythropoiesis | Q36787505 | ||
| Anemia in the elderly: how should we define it, when does it matter, and what can be done? | Q36900473 | ||
| Therapeutic potential of erythropoietin in cardiovascular disease: erythropoiesis and beyond | Q36947417 | ||
| Regulation of erythropoiesis by hypoxia-inducible factors | Q37063716 | ||
| Erythropoietic agents and the elderly | Q37098040 | ||
| A Red Carpet for Iron Metabolism. | Q39106718 | ||
| Erythropoietin Regulation by Angiotensin II. | Q39383729 | ||
| Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT. | Q39722840 | ||
| Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss | Q39831871 | ||
| Transcription factor GATA-1 and erythroid development | Q40870806 | ||
| Studies on hematopoietic stem cells: XI. Lack of erythroid burst-forming units (BFU-E) in patients with aplastic anemia | Q41661146 | ||
| Assessment of erythroid dysplasia by "difference from normal" in routine clinical flow cytometry workup. | Q41711144 | ||
| Cdk6 contributes to cytoskeletal stability in erythroid cells. | Q41949980 | ||
| Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib | Q41955541 | ||
| Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis | Q42130626 | ||
| HSP70 sequestration by free α-globin promotes ineffective erythropoiesis in β-thalassaemia | Q42152354 | ||
| Impaired formation of erythroblastic islands is associated with erythroid failure and poor prognosis in a significant proportion of patients with myelodysplastic syndromes | Q42399896 | ||
| Erythropoietin treatment of anemia associated with multiple myeloma | Q43756412 | ||
| A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life | Q44369408 | ||
| Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT). | Q44373728 | ||
| Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics | Q44590610 | ||
| HSP70, an erythropoiesis regulator that determines the fate of erythroblasts between death and differentiation | Q44907948 | ||
| A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. | Q45991834 | ||
| Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. | Q46402910 | ||
| Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa | Q46422375 | ||
| Hepcidin regulation in the anemia of inflammation | Q37193954 | ||
| Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications | Q37398124 | ||
| Regulation of oxygen homeostasis by hypoxia-inducible factor 1. | Q37443475 | ||
| Regulation of hepcidin and iron-overload disease | Q37463068 | ||
| Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions | Q37488486 | ||
| The therapeutic potential of erythropoiesis-stimulating agents for tissue protection: a tale of two receptors. | Q37679592 | ||
| GATA factor switching during erythroid differentiation | Q37705916 | ||
| The role of the renin-angiotensin system in the regulation of erythropoiesis | Q37733101 | ||
| Erythropoiesis stimulating agents and anaemia of end-stage renal disease | Q37742655 | ||
| Advancements in anemias related to chronic conditions | Q37771336 | ||
| Postpartum anemia I: definition, prevalence, causes, and consequences | Q37895161 | ||
| Erythroid proliferations in myeloid neoplasms | Q37966327 | ||
| Anemia and chronic kidney disease: making sense of the recent trials | Q38006040 | ||
| Low blood counts: immune mediated, idiopathic, or myelodysplasia. | Q38066912 | ||
| How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The use of iron supplementation to reduce ESA dosing in hemodialysis | Q38114158 | ||
| Erythropoiesis stimulating agents and other growth factors in low-risk MDS. | Q38186278 | ||
| New treatment approaches in chronic kidney disease-associated anaemia | Q38192002 | ||
| The ESA scenario gets complex: from biosimilar epoetins to activin traps | Q38205752 | ||
| Erythropoiesis: from molecular pathways to system properties | Q38283996 | ||
| An overview of molecular basis of iron metabolism regulation and the associated pathologies. | Q38406652 | ||
| New Treatment Approaches for the Anemia of CKD. | Q38587175 | ||
| Ineffective erythropoiesis and regulation of iron status in iron loading anaemias | Q38613789 | ||
| Reclassifying myelodysplastic syndromes: what's where in the new WHO and why. | Q38659504 | ||
| Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease | Q38666448 | ||
| Novel players in β-thalassemia dyserythropoiesis and new therapeutic strategies | Q38700727 | ||
| Metabolic regulation of hematopoietic stem cell commitment and erythroid differentiation | Q38731009 | ||
| Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia | Q38759271 | ||
| Pure erythroid leukemia | Q38779206 | ||
| Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis | Q38816577 | ||
| Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. | Q38831810 | ||
| Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis | Q38841795 | ||
| Advances in understanding the mechanisms of erythropoiesis in homeostasis and disease. | Q38904398 | ||
| Revisiting erythroleukemia | Q39016718 | ||
| Aplastic anemia and clonal evolution: germ line and somatic genetics | Q39027706 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hematology | Q103824 |
| anemia | Q5445 | ||
| polycythemia | Q933716 | ||
| neoplasm | Q1216998 | ||
| cell | Q7868 | ||
| neoplastic gene expression regulation | Q66660300 | ||
| P304 | page(s) | 1593-1603 | |
| P577 | publication date | 2018-10-01 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts | |
| P478 | volume | 103 |
Search more.